Northern Trust Corporation today commented on the results of the Federal Reserve’s 2022 Comprehensive Capital Analysis and Review (CCAR) and announced plans to increase its quarterly common stock dividend from $0.70 to $0.75 per common share, beginning in the third quarter of 2022.
Lilly Announced Tirzepatide Led to Greater Time in Range Compared to Insulin Degludec in Adults With Type 2 Diabetes in Surpass-3 CGM Sub-study
All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in adults with type 2 diabetes in a continuous glucose monitoring (CGM) sub-study1 of Eli Lilly and Company's (NYSE: LLY) phase 3 SURPASS-
